Patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT) for hematological malignancies are at high risk of infections. 1 The synergy of transplant conditioning and allogeneic effect of the graft will destroy the patient's immune system and in particular antiviral immunity may be impeded for a substantial period of time. Moreover, many patients may already have slumbering viral infections at transplant because the disease and its treatment have weakened their immune system. Immunocompetence is difficult to quantify but surrogate markers may help in assessing the degree of the patient's immunodeficiency. The number of CD4-positive T cells is such a marker but it may be inaccurate in patients going through multiple periods of chemotherapy- 2 or transplant conditioning-induced lymphopenia because the number of T cells may normalize without restoring immunity.
3 It is obvious that the level of the patient's immunocompetence is assessed best based on his genuine capacity to defend himself against infections.
Torque teno virus (TTV) is a small non-enveloped, singlestranded DNA Anellovirus that infects humans early in life. [4] [5] [6] Reports on the prevalence in the general population vary greatly, most likely owing to the different thresholds of the PCR techniques used for the detection of the viral genome. 6 It is currently believed that 490% of the population is infected but that the viral load in blood may remain undetectable because genome replication is efficiently controlled by the immune system. The latter is clearly illustrated by the fact that the viral load increases greatly after immune suppression given to prevent rejection of transplanted organs 7, 8 and that high copy numbers are present in the blood during secondary immune deficiencies in patients with AIDS 9 or after HSCT. 10, 11 As TTV is not sensitive to current antiviral prophylaxis/therapy, 8 the number of viral copies in the patient's blood may be an appropriate parameter to measure immunocompetence.
We have determined TTV-titers in 74 healthy blood donors and in 121 adult patients receiving first allogeneic grafts for hematological malignancies during the first 3-4 months of transplantation. Patients were transplanted for AML (n = 58), ALL (n = 15), myelodysplastic syndrome (MDS) (12) , non-Hodgkin lymphoma (NHL) (10), myeloproliferative syndrome (MPS) (6), multiple myeloma (9), HL (5), CML (3), CLL (1), myelodysplastic/ myeloproliferative syndrome (MDPS) (1) or acute plasmacytoid dendritic leukemia. 1 Further details such as (disease) status at transplant or other parameters with a potential impact on the patient's immunity are shown in the Table 1 .
We used a Taqman-based quantitative PCR with primers described by Moen et al. 12 with a detection limit of 25 viral copies/ml of plasma and a linear amplification range from 250 to 2.5 × 10 9 viral copies/ml. With this method, we detected TTV in 51/74 (69%) of healthy controls (median 170, range 0-5.4 × 10 4 copies/ml, left panel of the Figure 1 ). At transplant (blood sampled at day 4.3 ± 5.4), the bulk of patients had TTV-titers in the same range, but 30 patients (25%) harbored supranormal viral loads (defined as 490th percentile of healthy controls (1.2 × 10 4 copies/ ml of plasma)). Three months later, all patients with normal TTVtiters at transplant who were still available for follow-up (n = 77) had high numbers of viral copies in their blood. These patients had received different intensities of transplant conditioning (60% reduced intensity), different type of grafts (81% partially T-cell depleted) from HLA-identical siblings (35%), from matched unrelated donors (45%) or from mismatched related (8%) or unrelated (12%) donors but none of these parameters appeared to have had an impact on the levels of viral copies in the blood (data not shown). We did observe that TTV-titers in patients with GvHD (black symbols) who received immune suppression including prednisone tended to be higher than in patients without, but this difference barely reached significance (P = 0.043). Patients with normal TTV-titers at transplant remained so for a considerable time. At 1 month after transplantation, only a few patients (14%) harbored supranormal TTV-titers in their blood, whereas 56% did so at two months (data not shown). This lag time of 41 month is very similar to the one observed after the beginning of immunosuppression in organ transplantation. 7, 8 Hence, at transplant, the majority of patients still disposes of sufficient residual immunity to keep TTV in check while others already have lost this capacity. Interestingly, supranormal TTV-titers at transplant were strongly associated with the type of disease (right panel of the Figure 1 ). Viral copy numbers were high in patients with ALL or NHL while titers in patients with other malignancies were in the normal range.
Different degrees of immunodeficiency in patients with cancer are often attributed to the type of chemotherapy received 13 and it has been argued that in particular the corticosteroids in the protocols used to treat patients with ALL/NHL are accountable for their reduced immunity. Others have argued that disease specific features may be at least as important.
14 Although our cohort is too small to evaluate these hypotheses conclusively, our results do give substantial support to the latter. First, most patients with malignancies other than ALL/NHL had TTV-titers in the normal range at transplant although many had received chemotherapies with comparable toxicity. Furthermore, patients having received previous autologous transplants (21 non-ALL/NHL patients) were not different from other non-ALL/NHL patients and we found no correlations between TTV-titers and time between diagnosis and transplant (not shown). Second, we found no association between TTV-titers in ALL/NHL patients and the number of cycles (range 2-13) of chemotherapy they had received. In fact, four of six patients with Philadelphia-positive ALL (black dots) who had received only 2-3 cycles of chemotherapy harbored much higher viral copy numbers in their blood than the nine Philadelphia-negative ALL patients who had received an average of 10.6 ± 3.7 cycles. It is true that the Philadelphia-positive patients also received the tyrosine kinase inhibitor imatinib but it is unlikely that this drug would add much to the immunosuppression already induced by the chemotherapy. More importantly, none of the non-ALL/NHL patients who had received tyrosine kinase inhibitors such as imatinib (n = 5) or sorafenib (n = 5) were TTV-positive at transplant. Furthermore, the impact of corticosteroids also seemed negligible, because TTV-titers in (non-ALL/NHL) patients (2/20 TTV-positive) who had received comparable long-term prednisone (defined as a median dose of 410 mg/day for at least 3 months) were not different from titers in patients who had received chemotherapy without steroids (11/76 TTV-positive). Together, our findings would indeed suggest that the type of disease has more impact on the patient's immunity at transplant than the treatment previously received and it is tempting to speculate that lymphoid malignancies with large, destructive Log TTV copies/ml P< 0.0001 P < 0.0001 P =0.0017 Figure 1 . TTV-copy numbers per ml of plasma as determined by Taqman-based quantitative PCR adapted from Moen et al. 12 Depicted are titers in healthy controls (Ctrl, n = 74), in patients at transplant (at Tx, n = 121) and the highest TTV-titer observed in patients at 2-3 months after transplantation (2-3 m, n = 77) with (black symbols, n = 15) or without (n = 62, gray symbols) GvHD. The right panel shows TTV-titers at transplant in patients with AML (n = 58), with Ph + (n = 6, black symbols) or Ph − (n = 9, gray symbols) ALL, NHL (n = 10) or other hematological malignancies (n = 38). Comparison between the patient groups and healthy controls were performed with the Mann-Whitney test. Abbreviations: ASCT = autologous stem cell transplantation; IQR = interquartile range; TKI = tyrosine kinase inhibitor.
Letter to the Editor proliferations such as ALL and NHL have a more profound impact on immunity than other hematological malignancies. Since the last two decades, numerous studies have reported that patients with reduced immunity harbor high copy numbers of TTV in their blood. We believe that our data warrant further investigation into the relevance of TTV-titers in patients undergoing HSCT. TTV-titers may complement current tests used to assess the patient's immunity. Furthermore, TTV allowed to propagate in patients without sufficient adaptive immunity will still be tracked by toll-like receptor 9 on cells of the innate immune system and drive proinflammatory cytokine production
